Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of KHK6640 in Alzheimer's Disease
NCT02127476Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2014
- Primary completion
- May 2017
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing KHK6640 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events up to 7 months. Started Jul 2014; status: completed.
02
Drugs
KHK6640
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02127476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127476.